Biotech ETF PBE Slips While Equal-Weight Healthcare RSPH Gains

PBE traded at 93.52, down 0.13% on the day, while RSPH traded at 36.70, up 0.33%, as of 17:43 GMT on Sept. 15, 2026, in a session where the S&P 500 tracker fell 0.51%.

Two of the most commonly paired healthcare exchange-traded funds went in opposite directions on Tuesday. PBE, the biotech-and-genome fund, changed hands at 93.52, down 0.13% from a prior close of 93.64. RSPH, the equal-weight healthcare fund, traded at 36.70, up 0.33% from 36.58. Both readings are as of the last trade at 17:43 GMT on Sept. 15, 2026, with the market still open.

That small divergence is a fair miniature of the larger question investors face when choosing between them. As Motley Fool framed the comparison, PBE has delivered higher income and stronger returns, while RSPH offers broader diversification, lower costs and less drawdown risk. Those are not competing claims about the same thing. They are descriptions of two different machines.

What each fund is actually built to do

A biotech and genome fund concentrates capital in a single, binary-outcome corner of healthcare. Drug developers live and die on clinical trial readouts and regulatory decisions, which means returns cluster: a handful of winners can carry a portfolio, and a handful of failures can gut one. Concentration of that kind is why a biotech sleeve can post stronger trailing returns than a diversified peer — and why its declines from peak to trough, the drawdowns, tend to be deeper and longer.

An equal-weight healthcare fund does close to the opposite. Equal weighting means each holding is sized the same at rebalance rather than in proportion to its market value, so the largest pharmaceutical and managed-care names do not dominate the result. The portfolio spreads across pharma, devices, insurers, distributors and services. That structure dilutes any single blow-up, and it also dilutes any single moonshot. Lower cost typically follows from the simpler, rules-based index behind it.

Neither design is superior in the abstract. They answer different questions. The biotech fund answers "how do I get direct exposure to drug innovation?" The equal-weight healthcare fund answers "how do I own the healthcare economy without betting on which subsector wins?"

Tuesday's tape put both ahead of the broad market

The wider session was weak. The S&P 500 tracker fell 0.51% to $757.01, the Nasdaq 100 tracker dropped 0.64% to $704.66, and the Dow tracker was the softest of the three at $520.44, down 0.77%. Against that, PBE's 0.13% decline was a shallower loss than the broad market's, and RSPH's 0.33% gain was outright positive. Healthcare in both forms held up better than the tape on the day.

The intraday behaviour is worth a second look, because it cuts against the easy assumption that the biotech fund is always the twitchier of the two. PBE's session range ran from 92.62 to 93.53, a band worth roughly 0.97% of its prior close, on an illustrative basis. RSPH swung between 36.31 and 36.78, a band of about 1.28% of its prior close. On this one session, the diversified fund moved through a wider relative range than the concentrated one — a reminder that single-day volatility is noise, and that the drawdown argument for RSPH is a claim about multi-month declines, not about any given Tuesday.

Income, cost and the gap that compounds

The income difference favours PBE, according to the comparison, while the cost advantage sits with RSPH. Both matter, and they work on different timescales. Yield shows up in cash distributions the investor can see. The expense ratio — the annual percentage a fund deducts from assets to run itself — never shows up as a line item at all. It is subtracted quietly from net asset value every day, which is precisely why it is easy to ignore and hard to escape.

Over a holding period measured in decades, a lower expense ratio is one of the few advantages in investing that is guaranteed in advance. Higher trailing returns are not guaranteed in advance; they are a report on what already happened. That asymmetry is the strongest argument in RSPH's favour for a core, long-horizon allocation, and it is unaffected by whatever biotech does next quarter.

Conversely, the income argument for PBE deserves scrutiny rather than acceptance. Distribution yield on an equity fund is a function of what the underlying holdings pay and of how capital gains are realised. It is not a bond coupon and should not be treated as one, particularly in a sector where many constituents are pre-revenue.

Sizing the two against each other

The per-share prices are not a valuation signal — they reflect how each fund was struck and split, nothing more. At Tuesday's levels PBE trades at roughly 2.5 times RSPH's share price on an illustrative basis, which means a fixed-dollar allocation buys about two and a half times as many RSPH shares. For anyone building positions with periodic contributions, that affects granularity, not merit.

The more useful framing is role. A portfolio that already holds a broad index fund carries meaningful healthcare exposure inside it, weighted toward the giants. Adding an equal-weight healthcare fund tilts that exposure away from the megacaps and toward the mid-tier. Adding a biotech fund does something categorically different: it introduces a risk factor the broad index barely expresses, with return outcomes that do not look like the market's.

What to watch from here

Three things will decide which structure looks smarter a year from now. The first is the clinical and regulatory calendar, which drives biotech returns far more than macro data does — a cluster of positive readouts lifts PBE in a way no equal-weight fund can match. The second is the policy environment for drug pricing and managed care, which hits RSPH's insurers and distributors directly. The third is the rate path, since long-duration, cash-burning drug developers are among the most rate-sensitive equities in the market.

For an investor who wants healthcare to behave like a defensive ballast, the equal-weight fund is the closer fit. For one who wants the sector to be a growth engine and can sit through deep declines without selling, the biotech fund is. The honest answer to the either/or question is that the choice is downstream of a decision about risk tolerance, not upstream of it.

Key facts

• PBE last trade: 93.52, -0.13% (17:43 GMT, Sept. 15, 2026)
• RSPH last trade: 36.70, +0.33% (17:43 GMT, Sept. 15, 2026)
• S&P 500 tracker (SPY): $757.01, -0.51% on the day
• Core trade-off: PBE: higher income, stronger returns; RSPH: broader diversification, lower cost, lower drawdown

Frequently asked questions

How did PBE and RSPH trade on Sept. 15, 2026?

As of the last trade at 17:43 GMT on Sept. 15, 2026, PBE was at 93.52, down 0.13% from a prior close of 93.64, with a session range of 92.62 to 93.53. RSPH was at 36.70, up 0.33% from a prior close of 36.58, with a range of 36.31 to 36.78. The market was still open.

What does equal weighting mean in an ETF?

Equal weighting sizes every holding in the fund identically at each rebalance, rather than in proportion to company market value. In a healthcare fund, that stops the largest pharmaceutical and managed-care names from dominating returns and gives mid-sized constituents the same influence as giants. It spreads risk more evenly but also dilutes the effect of any single outsized winner.

Which fund carries more drawdown risk?

PBE carries the higher drawdown risk. Biotech returns depend on binary clinical trial and regulatory outcomes, so concentrated exposure to drug developers produces deeper and longer peak-to-trough declines. RSPH, spread across pharma, devices, insurers, distributors and services on an equal-weight basis, is described as having lower drawdown risk alongside broader diversification and lower costs.

Why does an expense ratio matter more than trailing returns?

An expense ratio is the annual percentage a fund deducts from assets to operate. It is certain in advance and compounds against the investor every year, yet never appears as a visible line item because it is taken out of net asset value. Trailing returns, by contrast, describe what already happened and carry no guarantee of repeating.

How did healthcare ETFs compare with the broad market that day?

Both held up better than the major benchmarks. The S&P 500 tracker fell 0.51% to $757.01, the Nasdaq 100 tracker dropped 0.64% to $704.66 and the Dow tracker lost 0.77% to $520.44. PBE's decline of 0.13% was shallower than all three, and RSPH's 0.33% gain was positive on a broadly negative session.

Does the higher share price of PBE mean it is more expensive?

No. A fund's per-share price reflects how it was originally struck and any subsequent splits, not its valuation or cost. At the Sept. 15 levels PBE trades at roughly 2.5 times RSPH's share price, so a fixed-dollar purchase buys fewer PBE shares. That affects position granularity only. The meaningful cost comparison is the expense ratio.

Sources

• PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors? — Motley Fool

Photo: https://kaboompics.com/ · Pexels Licence — source